Journal of Clinical Toxicology
Open Access

Abstract

The Efficacy of Shenyankangfu Tablets Combined With Losartan Potassium for Chronic Glomerulonephritis: A Systematic Review and Meta-Analysis

Yang Yang, Jiahui Jin, Yaxin Gao, Dandan Zhu, Heting Zhang, Yuqing Xue, Hongwu Wang and Tieniu Zhao*

Objective: To conduct a systematic review of the efficacy and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of chronic glomerulonephritis.

Method: Through searching CNKI, VIP, Wanfang, Chinese Biomedical Literature Service System, American Clinical Trial Registry, Embase, Web of Science, PubMed, and Cochrane Library databases. The retrieval time was from the establishment of the database to June 1, 2023. All the Randomized Controlled Trials (RCTS) of Shenyankangfu tablets combined with losartan potassium in the treatment of renal chronic glomerulonephritis were collected, and the data of clinical studies meeting the inclusion criteria was extracted. Meta-analysis was performed using Review Manager 5.4 software. The study was registered with PROSPERO, CRD42024499186.

Results: A total of 480 relevant literature was retrieved, and 25 eligible randomized controlled trials were selected, for a total of 2050 participants, including 1025 in the observation group and 1025 in the control group. The results of Meta-Analysis showed: Compared with losartan potassium alone in the treatment of chronic glomerulonephritis, Shenyankangfu tablets combined with losartan potassium can improve the clinical effective rate [RR=1.26, 95% CI (1.20, 1.31) , P＜0.001].The reductions of blood urea nitrogen [MD=-0.78, 95% CI (-1.03, -0.53), P＜0.001], blood creatinine [MD=-5.06, 95% CI (-8.01, -2.12), P＜0.001], 24-hour urine protein quantification [MD=-0.51, 95% CI (-0.63, -0.40), P＜0.001], urinary NAG enzyme [MD=-6.77, 95% CI (-12.03,-1.51), P<0.001] and the incidence of adverse reactions [RR=0.59, 95% CI (0.36, 0.95), P＜0.001] were better than losartan potassium alone, and the difference was statistically significant.

Conclusion: Shenyankangfu tablets combined with losartan potassium can improve the clinical treatment efficiency of chronic glomerulonephritis, and can effectively reduce the occurrence of blood urea nitrogen, blood creatinine, 24-hour urine protein quantification, urinary NAG enzyme, and adverse reactions.

Published Date: 2024-05-17; Received Date: 2024-04-16